Glaucoma Drop Intolerance in a Patient with COPD
A 74-year-old man with primary open-angle glaucoma has been stable on latanoprost 0.005% nightly and timolol 0.5% twice daily for four years. Today IOP is 16 mmHg OD and 15 mmHg OS, with a target of 15 mmHg and mild-to-moderate optic nerve cupping. He has chronic obstructive pulmonary disease and has been hospitalized twice in the past six months for exacerbations. He reports increasing fatigue, exercise intolerance, and a resting pulse of 52 beats per minute. He has a pacemaker and asks you to "just stop the timolol" because he read that beta-blockers can worsen breathing. He wants to know whether latanoprost alone will protect his vision. He is adherent to both drops, uses punctal occlusion, lives alone, and drives. He has no sulfa allergy and no history of uveitis.
1. How would you assess whether timolol is contributing to his symptoms, and what is your initial plan?
Read the worked answer
The timolol is a plausible contributor and the risk-benefit calculus has shifted. Non-selective topical beta-blockers are systemically absorbed and can cause bronchospasm, bradycardia, and fatigue; two COPD hospitalizations in six months plus a resting pulse of 52 and exercise intolerance are meaningful signals, even with a pacemaker. I would not simply accept 'just stop it' or dismiss the symptoms. I would check blood pressure and pulse, ask about inhaler and nebulizer use and the timing of symptoms relative to drops, and review cardiology and pulmonary notes. Because the target IOP is 15 and he has cupping, stopping timolol without a replacement risks an IOP rise. I would explain that latanoprost alone may be insufficient and discuss alternatives: selective laser trabeculoplasty, brimonidine, dorzolamide, or a fixed combination that avoids a nonselective beta-blocker. I would avoid carte blanche switching to betaxolol; it is cardioselective but not risk-free. The decision should be shared and documented, with the primary care physician and pulmonologist informed.
2. If he insists on stopping timolol now, what monitored transition would you arrange?
Read the worked answer
If he insists on stopping timolol now, I would not abandon him; I would create a monitored transition. I would stop the timolol, start an alternative such as brimonidine twice daily or refer for selective laser trabeculoplasty, and schedule an IOP check within 4–6 weeks, sooner if there is optic nerve risk or symptoms. I would give a written action plan for shortness of breath, wheeze, or pulse below 50, and tell him to contact his pulmonologist. I would emphasize that IOP control is a long game: a short-term rise may not cause immediate symptoms but can add to cumulative optic nerve damage. I would also verify adherence and technique, because he uses punctal occlusion already. If the IOP rises above target or the visual field shows progression, I would escalate to selective laser trabeculoplasty or a combination drop. The key is not to trade a pulmonary risk for an unmonitored glaucoma risk.
3. What would you document, and how would you communicate the plan to the rest of his care team?
Read the worked answer
Documentation should show a risk-benefit discussion, not just a prescription change. I would record the COPD history, hospitalizations, pulse, symptoms, current IOP and target, optic nerve appearance, and the fact that timolol can be systemically absorbed. I would note the options discussed-continue with pulmonary input, stop and replace, selective laser trabeculoplasty-and the patient's preference. I would document that abrupt discontinuation can produce an IOP rise and that a follow-up interval was set. I would send a concise note to the primary care physician and pulmonologist and ask them to flag any beta-blocker sensitivity. I would also document the counseling on warning signs and the plan if IOP is above target at follow-up. If the patient later has a COPD exacerbation, the record should make clear that the topical beta-blocker was considered and addressed. This protects the patient and demonstrates a defensible, patient-centered rationale.